(Q37696351)

22 August 2017

1 reference

title

A review of clinical trials of anti-VEGF agents for diabetic retinopathy (English)

1 reference

22 August 2017

Benjamin P Nicholson

1

1 reference

PubMed ID

20174816

22 August 2017

Andrew P Schachat

series ordinal

2

1 reference

22 August 2017

20 February 2010

1 reference

Graefe's Archive for Clinical and Experimental Ophthalmology

22 August 2017

1 reference

22 August 2017

248

1 reference

22 August 2017

7

1 reference

22 August 2017

915-930

1 reference

https://scigraph.springernature.com/pub.10.1007/s00417-010-1315-z

22 August 2017

0 references

cites work

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1315-Z

Risk factors for ciliochoroidal effusion after panretinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1315-Z

Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1315-Z

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1315-Z

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

12 December 2020

Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation

1 reference

12 December 2020

Hypoxic regulation of vascular endothelial growth factor in retinal cells

1 reference

12 December 2020

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

12 December 2020

Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials

1 reference

12 December 2020

Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population

1 reference

12 December 2020

Phenotypic and genotypic heterogeneity in familial Milroy lymphedema

1 reference

12 December 2020

Prevalence of diabetic retinopathy among subjects with known diabetes in China: the Beijing Eye Study

1 reference

12 December 2020

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1 reference

12 December 2020

Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema

1 reference

12 December 2020

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

1 reference

12 December 2020

Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells

1 reference

12 December 2020

Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

1 reference

12 December 2020

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study

1 reference

12 December 2020

Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition

1 reference

12 December 2020

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

1 reference

12 December 2020

Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.

1 reference

12 December 2020

Bevacizumab (Avastin) for the treatment of ocular disease

1 reference

12 December 2020

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

1 reference

12 December 2020

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

12 December 2020

Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study.

1 reference

12 December 2020

Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.

1 reference

12 December 2020

Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema

1 reference

12 December 2020

Vascular endothelial growth factor in eye disease

1 reference

12 December 2020

Overview of epidemiologic studies of diabetic retinopathy

1 reference

12 December 2020

Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy

1 reference

12 December 2020

Global data on visual impairment in the year 2002

1 reference

12 December 2020

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

1 reference

12 December 2020

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

1 reference

12 December 2020

Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study).

1 reference

12 December 2020

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.

1 reference

12 December 2020

Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study

1 reference

12 December 2020

Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years

1 reference

12 December 2020

VEGF164Is Proinflammatory in the Diabetic Retina

1 reference

12 December 2020

Macular edema following panretinal photocoagulation

1 reference

12 December 2020

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1

1 reference

12 December 2020

Pegaptanib for neovascular age-related macular degeneration

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

1 reference

12 December 2020

VEGF-initiated blood-retinal barrier breakdown in early diabetes.

1 reference

12 December 2020

Risk factors for Type II diabetes and diabetic retinopathy in a mexican-american population: Proyecto VER.

1 reference

12 December 2020

Ranibizumab for neovascular age-related macular degeneration

1 reference

12 December 2020

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

1 reference

12 December 2020

Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

1 reference

12 December 2020

VEGF increases retinal vascular ICAM-1 expression in vivo.

1 reference

12 December 2020

Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial

1 reference

12 December 2020

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

1 reference

12 December 2020

Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Vascular-specific growth factors and blood vessel formation

1 reference

12 December 2020

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

1 reference

12 December 2020

Review of anti-VEGF therapy in proliferative diabetic retinopathy.

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

1 reference

12 December 2020

Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection

1 reference

12 December 2020

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

1 reference

12 December 2020

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therap

1 reference

12 December 2020

Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy

1 reference

12 December 2020

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

1 reference

12 December 2020

A new look at an old treatment for diabetic macular edema

1 reference

12 December 2020

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

12 December 2020

Detection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-injured rat retina

1 reference

12 December 2020

The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study

1 reference

12 December 2020

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

1 reference

12 December 2020

Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Localization of vascular endothelial growth factor in human retina and choroid

1 reference

12 December 2020

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial

1 reference

12 December 2020

Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro

1 reference

12 December 2020

Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery

1 reference

12 December 2020

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

1 reference

12 December 2020

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years

1 reference

12 December 2020

Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid.

1 reference

12 December 2020

Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

1 reference

12 December 2020

Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

1 reference

12 December 2020

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

1 reference

12 December 2020

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

1 reference

12 December 2020

10.1007/S00417-010-1315-Z

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20174816